ArticleFrontiers in microbiology2020
Evolutionary Dynamics and Dissemination Pattern of the SARS-CoV-2 Lineage B.1.1.33 During the Early Pandemic Phase in Brazil.
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SARS-CoV-2 Genomic Surveillance in Brazil: A Systematic Review with Scientometric Analysis.Viruses · 2022Pooled it
- Comparative spatial-temporal analysis of SARS-CoV-2 lineages B.1.1.33 and BQ.1.1 Omicron variant across pandemic phases.Scientific reports · 2025Article
- Clinical characteristics, SARS-CoV-2 variants, and outcomes of adults hospitalized due to COVID-19 in Latin American countries.Clinics (Sao Paulo, Brazil) · 2025Observational
- Spatiotemporal Dynamics of SARS-CoV-2 Variants During the First Year of the Pandemic Highlight the Earlier Emergence of the Zeta Variant of Interest in Brazil.Pathogens (Basel, Switzerland) · 2024Article
- Higher Frequency of SARS-CoV-2 RNA Shedding by Cats than Dogs in Households with Owners Recently Diagnosed with COVID-19.Viruses · 2024Article
- SARS-CoV-2 transmission in a highly vulnerable population of Brazil: a household cohort study.Lancet regional health. Americas · 2024Article
- Analyzing the COVID-19 Transmission Dynamics in Acre, Brazil: An Ecological Study.Epidemiologia (Basel, Switzerland) · 2024Article
- Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.Microbiology spectrum · 2024Article
- SARS-CoV-2 strains and clinical profiles of COVID-19 patients in a Southern Brazil hospital.Frontiers in immunology · 2024Article
- SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.The Journal of infectious diseases · 2023Article
- Genomic epidemiology of SARS-CoV-2 variants during the first two years of the pandemic in Colombia.Communications medicine · 2023Article
- Infectious SARS-CoV-2 Particles from Rectal Swab Samples from COVID-19 Patients in Brazil.Viruses · 2023Article
- A straightforward one-step strategy for SARS-CoV-2 diagnosis and screening of variants of concern: a multicentre study.Memorias do Instituto Oswaldo Cruz · 2023Article
- Associations of SARS-CoV-2 cycle threshold values with age, gender, sample collection setting, and pandemic period.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023Article
- Cohort-profile: Household transmission of SARS-CoV-2 in a low-resource community in Rio de Janeiro, Brazil.BMJ open · 2022Article
- Genomic surveillance: Circulating lineages and genomic variation of SARS-CoV-2 in early pandemic in Ceará state, Northeast Brazil.Virus research · 2022Article
- Article
- Emergence and Spread of the SARS-CoV-2 Variant of Concern Delta across Different Brazilian Regions.Microbiology spectrum · 2022Article
- New rules for genomics-informed COVID-19 responses-Lessons learned from the first waves of the Omicron variant in Australia.PLoS genetics · 2022Article
- Phylodynamic analysis of SARS-CoV-2 spread in Rio de Janeiro, Brazil, highlights how metropolitan areas act as dispersal hubs for new variants.Microbial genomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A previous study demonstrates that most of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Brazilian strains fell in three local clades that were introduced from Europe around late February 2020. Here we investigated in more detail the origin of the major and most widely disseminated SARS-CoV-2 Brazilian lineage B.1.1.33. We recovered 190 whole viral genomes collected from 13 Brazilian states from February 29 to April 31, 2020 and combined them with other B.1.1 genomes collected globally. Our genomic survey confirms that lineage B.1.1.33 is responsible for a variable fraction of the community viral transmissions in Brazilian states, ranging from 2% of all SARS-CoV-2 genomes from Pernambuco to 80% of those from Rio de Janeiro. We detected a moderate prevalence (5-18%) of lineage B.1.1.33 in some South American countries and a very low prevalence (<1%) in North America, Europe, and Oceania. Our study reveals that lineage B.1.1.33 evolved from an ancestral clade, here designated B.1.1.33-like, that carries one of the two B.1.1.33 synapomorphic mutations. The B.1.1.33-like lineage may have been introduced from Europe or arose in Brazil in early February 2020 and a few weeks later gave origin to the lineage B.1.1.33. These SARS-CoV-2 lineages probably circulated during February 2020 and reached all Brazilian regions and multiple countries around the world by mid-March, before the implementation of air travel restrictions in Brazil. Our phylodynamic analysis also indicates that public health interventions were partially effective to control the expansion of lineage B.1.1.33 in Rio de Janeiro because its median effective reproductive number (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.